2012
DOI: 10.1093/bja/aes137
|View full text |Cite
|
Sign up to set email alerts
|

Three cases of suspected sugammadex-induced hypersensitivity reactions

Abstract: Neuromuscular blocking agents have been implicated in 60-70% of anaphylactic events associated with anaesthesia. We report two cases of probable hypersensitivity reaction to sugammadex and an additional suspected but less supported case of possible immune-mediated reaction or other adverse reaction. The patients were given a bolus of sugammadex 100 mg immediately before extubation. In all three patients, a possible allergic reaction was suspected within 4 min of sugammadex administration, but with different de… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
54
1

Year Published

2013
2013
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 83 publications
(57 citation statements)
references
References 16 publications
2
54
1
Order By: Relevance
“…This has been confirmed by several case reports of allergic reactions in patients who had received sugammadex for the first time 96–99. Reviews of both the published approval studies100 and of retrospective data from a single center in Japan over a period of 1 year97 show an incidence below 1%.…”
Section: Safetymentioning
confidence: 69%
“…This has been confirmed by several case reports of allergic reactions in patients who had received sugammadex for the first time 96–99. Reviews of both the published approval studies100 and of retrospective data from a single center in Japan over a period of 1 year97 show an incidence below 1%.…”
Section: Safetymentioning
confidence: 69%
“…Some reports described sugammadex‐induced anaphylactic reactions in adults . A previous study reported that incidence proportion of sugammadex‐induced anaphylactic reactions was estimated to be 0.003% .…”
Section: Introductionmentioning
confidence: 99%
“…The manufacturer recommends special caution using sugammadex in patients with highly depressed hepatic or renal function, infants, and in obstetric cases [5]. Hypersensitivity, which has caused a delay in FDA approval in the United States, is also a concern, as well as other adverse effects [6]. A randomized, safety assessor-blinded trial that included 128 Korean patients undergoing general anesthesia has been conducted.…”
mentioning
confidence: 99%